- Home
- MTNB vs GLMD Comparison
MTNB vs GLMD Comparison
Compare MTNB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- GLMD
- Stock Information
- Founded
- MTNB 2013
- GLMD 2000
- Country
- MTNB United States
- GLMD Israel
- Employees
- MTNB N/A
- GLMD N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- GLMD Health Care
- Exchange
- MTNB Nasdaq
- GLMD Nasdaq
- Market Cap
- MTNB 3.1M
- GLMD 3.0M
- IPO Year
- MTNB N/A
- GLMD 2014
- Fundamental
- Price
- MTNB $0.71
- GLMD $1.24
- Analyst Decision
- MTNB Hold
- GLMD Hold
- Analyst Count
- MTNB 1
- GLMD 1
- Target Price
- MTNB N/A
- GLMD N/A
- AVG Volume (30 Days)
- MTNB 73.5K
- GLMD 4.7M
- Earning Date
- MTNB 05-20-2025
- GLMD 05-29-2025
- Dividend Yield
- MTNB N/A
- GLMD N/A
- EPS Growth
- MTNB N/A
- GLMD N/A
- EPS
- MTNB N/A
- GLMD N/A
- Revenue
- MTNB N/A
- GLMD N/A
- Revenue This Year
- MTNB N/A
- GLMD N/A
- Revenue Next Year
- MTNB N/A
- GLMD N/A
- P/E Ratio
- MTNB N/A
- GLMD N/A
- Revenue Growth
- MTNB N/A
- GLMD N/A
- 52 Week Low
- MTNB $0.48
- GLMD $1.21
- 52 Week High
- MTNB $9.60
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- MTNB 63.45
- GLMD 40.20
- Support Level
- MTNB $0.57
- GLMD $1.15
- Resistance Level
- MTNB $0.65
- GLMD $1.69
- Average True Range (ATR)
- MTNB 0.07
- GLMD 0.22
- MACD
- MTNB 0.01
- GLMD 0.00
- Stochastic Oscillator
- MTNB 51.79
- GLMD 5.88
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.